394 450

Cited 189 times in

Early onset severe and late-onset mild Charcot–Marie–Tooth disease with mitofusin 2 (MFN2) mutations

 K. W. Chung  ;  S. B. Kim  ;  K. D. Park  ;  K. G. Choi  ;  J. H. Lee  ;  H. W. Eun  ;  J. S. Suh  ;  J. H. Hwang  ;  W. K. Kim  ;  B. C. Seo  ;  S. H. Kim  ;  I. H. Son  ;  S. M. Kim  ;  I. N. Sunwoo  ;  B. O. Choi 
 BRAIN, Vol.129(8) : 2103-2118, 2006 
Journal Title
Issue Date
Adolescent ; Adult ; Age of Onset ; Amino Acid Sequence ; Brain/pathology ; Charcot-Marie-Tooth Disease/genetics* ; Charcot-Marie-Tooth Disease/pathology ; Child ; Disability Evaluation ; Female ; GTP Phosphohydrolases ; Humans ; Magnetic Resonance Imaging ; Male ; Membrane Proteins/genetics* ; Microscopy, Electron ; Middle Aged ; Mitochondrial Proteins/genetics* ; Molecular Sequence Data ; Mutation* ; Neural Conduction ; Optic Atrophies, Hereditary/genetics ; Pedigree ; Phenotype ; Severity of Illness Index ; Sural Nerve/ultrastructure
Charcot–Marie–Tooth disease ; CMT2A ; HMSN VI ; mitofusin 2 (MFN2)
Mutations in the mitofusin 2 (MFN2) gene, which encodes a mitochondrial GTPase mitofusin protein, have recently been reported to cause both Charcot-Marie-Tooth 2A (CMT2A) and hereditary motor and sensory neuropathy VI (HMSN VI). It is well known that HMSN VI is an axonal CMT neuropathy with optic atrophy. However, the differences between CMT2A and HMSN VI with MFN2 mutations remained to be clarified. Therefore, we studied the phenotypic characteristics of CMT patients with MFN2 mutations. Mutations in MFN2 were screened in 62 unrelated axonal CMT neuropathy families. We calculated CMT neuropathy scores (CMTNSs) and functional disability scales (FDSs) to quantify disease severity. Twenty-one patients with the MFN2 mutations were studied by brain MRI. Ten pathogenic mutations were identified in 26 patients from 15 families (24.2%). Six of these mutations had not been reported, and de novo mutations were observed in five families (33.3%). The electrophysiological patterns of affected individuals with the MFN2 mutations were typical of axonal CMT; however, the clinical and electrophysiological characteristics were markedly different in early (<10 years) and late disease-onset (> or =10 years) groups. All patients with an early onset had severe CMTNS (> or =21) and FDS (6 or 7), whereas most patients with late onset had mild CMTNS (< or =10) and FDS (< or =3). We identified two HMSN VI families with the R364W mutation in the early onset group; however, two other families with the same mutation did not have optic atrophy. In addition, two early onset families with R94W mutations, previously reported for HMSN VI, did not have visual impairment. Interestingly, eight patients had periventricular and subcortical hyperintense lesions by brain MRI. In the late-onset group, three patients had sensorineural hearing loss and two had bilateral extensor plantar responses. We found that MFN2 mutations are the major cause of axonal CMT neuropathy, and that they are associated with variable CNS involvements. Phenotypes were significantly different in the early and late disease-onset groups. Our findings suggest that HMSN VI might be a variant of the early onset severe CMT2A phenotype.
Files in This Item:
T200600401.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Neurology (신경과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
Yonsei Authors
Kim, Se Hoon(김세훈) ORCID logo https://orcid.org/0000-0001-7516-7372
Kim, Seung Min(김승민) ORCID logo https://orcid.org/0000-0002-4384-9640
Sunwoo, Il Nam(선우일남)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.